World's Best Scientists 2026 revealed!
Francesco Cognetti

Francesco Cognetti

D-Index & Metrics

Medicine

D-Index
82
Citations
36192
World Ranking
15881
National Ranking
621

Francesco Cognetti publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Francesco Cognetti sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 691 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Francesco Cognetti D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Francesco Cognetti sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 82 D-Index — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Francesco Cognetti is affiliated with the Sapienza University of Rome in Italy. Their primary field of research is Medicine, with a focus on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging, and Molecular Biology. Their work encompasses several specialized topics, notably Cancer Immunotherapy and Biomarkers, Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, CAR-T cell therapy research, HER2/EGFR in Cancer Research, Radiomics and Machine Learning in Medical Imaging, and Immunotherapy and Immune Responses.

Their recent published works include:

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial, 2021, The Lancet Oncology
  • Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma, 2020, Journal of Clinical Oncology
  • Exploring CT Texture Parameters as Predictive and Response Imaging Biomarkers of Survival in Patients With Metastatic Melanoma Treated With PD-1 Inhibitor Nivolumab: A Pilot Study Using a Delta-Radiomics Approach, 2021, Frontiers in Oncology
  • The immersive experience of virtual reality during chemotherapy in patients with early breast and ovarian cancers: The patient's dream study, 2022, Frontiers in Oncology
  • Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP), 2024, Journal of Clinical Oncology

Frequent coauthors who have collaborated extensively with Francesco Cognetti include:

  • Paolo Marchetti
  • Paolo A. Ascierto
  • Alessandra Fabi
  • Diana Giannarelli
  • Michelino De Laurentiis

The principal publication venues where Francesco Cognetti's work appears most frequently are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Frontiers in Oncology
  • Tumori Journal
  • Zenodo (CERN European Organization for Nuclear Research)

Best Publications

  • Nivolumab in previously untreated melanoma without BRAF mutation.

    Caroline Robert;Georgina V. Long;Benjamin Brady;Caroline Dutriaux

  • Postoperative Irradiation With or Without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer

    Jacques Bernier;Christian Domenge;Mahmut Ozsahin;Katarzyna Matuszewska

  • Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

    Michael Marty;Francesco Cognetti;Dominique Maraninchi;Raymond Snyder

  • Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial

    Eric Pujade-Lauraine;Jonathan A Ledermann;Frédéric Selle;Val Gebski

  • Randomized Study of Adjuvant Chemotherapy for Completely Resected Stage I, II, or IIIA Non–Small-Cell Lung Cancer

    Giorgio V. Scagliotti;Roldano Fossati;Valter Torri;Lucio Crinò

  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    Miguel Martin;Frankie A Holmes;Bent Ejlertsen;Suzette Delaloge

  • Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.

    Serrone L;Zeuli M;Sega Fm;Cognetti F

  • PTEN: Multiple Functions in Human Malignant Tumors

    Michele Milella;Italia Falcone;Fabiana Conciatori;Ursula Cesta Incani

  • Cancer in the elderly: why so badly treated?

    I.S. Fentiman;U. Tirelli;S. Monfardini;M. Schneider

  • A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis

    Andrea Alimonti;Caterina Nardella;Zhenbang Chen;John G. Clohessy

  • Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.

    Donatella Del Bufalo;Ludovica Ciuffreda;Daniela Trisciuoglio;Marianna Desideri

  • Neuroprotective Effect of Vitamin E Supplementation in Patients Treated With Cisplatin Chemotherapy

    Andrea Pace;Antonella Savarese;Mauro Picardo;Vittoria Maresca

  • Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck A phase III study of the EORTC Head and Neck Cancer Cooperative Group

    M. Clavel;J. B. Vermorken;F. Cognetti;P. Cappelaere

  • Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone

    F Roila;M Tonato;F Cognetti;E Cortesi

  • Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial

    Paolo A. Ascierto;Georgina V. Long;Georgina V. Long;Caroline Robert;Benjamin Brady

  • Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, As First-Line Therapy in Patients With Metastatic Breast Cancer Previously Treated With Anthracycline Chemotherapy

    Henri Roché;Louise Yelle;Francesco Cognetti;Louis Mauriac

  • Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

    F. Cognetti;E. M. Ruggeri;A. Felici;M. Gallucci

  • Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial

    A. Pace;D. Giannarelli;E. Galiè;A. Savarese

  • HER2 and response to paclitaxel in node-positive breast cancer.

    Gianluigi Ferretti;Alessandra Felici;Francesco Cognetti

  • Neuroprotective E ffect o f V itamin E S upplementation i n Patients T reated W ith C isplatin C hemotherapy

    Andrea Pace;Antonella Savarese;Mauro Picardo;Vittoria Maresca

Frequent Co-Authors

Diana Giannarelli
Diana Giannarelli Sapienza University of Rome
Michele Milella
Michele Milella University of Verona
Marcella Mottolese
Marcella Mottolese IRCCS Regina Elena Institute
Giampaolo Tortora
Giampaolo Tortora University of Verona
Mario Mandalà
Mario Mandalà European Institute of Oncology
Sandro Barni
Sandro Barni Mario Negri Institute for Pharmacological Research
Sabino De Placido
Sabino De Placido University of Naples Federico II
Alfredo Falcone
Alfredo Falcone University of Pisa
Michele Maio
Michele Maio University of Siena
James A. McCubrey
James A. McCubrey East Carolina University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a medical career doesn’t always mean taking the traditional route. Many students today are considering flexible online options that lead to rewarding healthcare roles. For nurses looking to advance, cheap rn to bsn programs offer a cost-effective way to build on your nursing credentials while working.

For those who don’t have a nursing background but want to enter advanced nursing roles, direct entry nurse practitioner programs for non-nurses online provide a pathway to an MSN and a faster route into nurse practitioner positions.

If you’re at the beginning of your healthcare journey, consider the online adn programs for non nurses. These programs make it possible for students without prior nursing experience to earn their associate degree in nursing through flexible study options.

Not all healthcare careers require patient care. For those interested in the administrative side of medicine, check out the best medical billing and coding schools online, where you can study remotely and access financial aid opportunities.

Best Scientists Citing Francesco Cognetti

Trending Scientists

Recently Published Articles